DRUG
HS-20094
Administrated by subcutaneous injection once a week
Status
Completed
Phase
Phase 2
Enrollment
275
Locations
1
Results
Not posted
Publications
0
Study summary
This is a 32-week, phase 2, randomized study, HS-20094 and placebo were double-blind, dulaglutide was open-label. Adults with T2D inadequately controlled with diet and exercise alone or with stable metformin, an HbA1c (glycated hemoglobin) ≥53 to ≤91 mmol/mol (≥7.0 % to≤10.5 %) were randomly assigned to receive 5 mg HS-20094, 10 mg HS-20094, 15 mg HS-20094, placebo, or 1.5 mg dulaglutide subcutaneously for 32 weeks. The primary endpoint was change in HbA1C from baseline to 32 weeks, and secondary endpoints included change in fasting glucose, body weight and several additional measures relevant for cardiovascular risks.
Interventions
DRUG
Administrated by subcutaneous injection once a week
DRUG
Administrated by subcutaneous injection once a week
DRUG
Administrated by subcutaneous injection once a week
Timeline
First posted
Mar 30, 2025
Study start
Feb 6, 2024
Primary completion
Mar 7, 2025
Study completion
Apr 9, 2025
Results posted
Not reported
Registry updated
Aug 1, 2025
Outcomes
The change of HbA1c in the patients
Time frame · From baseline to week 32
The percentage of patients reaching the HbA1c target of ≤ 6.5%
Time frame · From baseline to week 32
The percentage of patients reaching the HbA1c target of<7.0%
Time frame · From baseline to week 32
The change in fasting blood glucose
Time frame · From baseline to week 32
The change in C peptide
Time frame · From baseline to week 32
The change of fasting insulin in the patients
Time frame · From baseline to week 32
The change in body weight
Time frame · From baseline to week 32
The percentage of patients with 5% or greater body weight loss
Time frame · From baseline to week 32
Eligibility
Inclusion Criteria: 1. Male or female patients 18 to 75 years of age, inclusive 2. Patients were diagnosed with T2DM for at least 3 months before screening. 3. Have an HbA1c value at screening of ≥7.0% and ≤10.5% and treated with diet and exercise alone or a stable dose of metformin (either immediate release or extended release, ≥1000mg/day and not more than the locally approved dose) for at least 2 months prior to screening 4. Body mass index (BMI)≥ 22 kg/m2. Exclusion Criteria: 1. Type 1 diabetes, gestational diabetes, monogenic diabetes, secondary diabetes, or undetermined diabetes as assessed by the investigator 2. Acute or chronic pancreatitis at any time before screening, or serum lipase/amylase above the upper limit of normal at screening 3. A history of grade 3 hypoglycemia (hypoglycemia with a serious event of consciousness and/or physical alteration requiring assistance from another person for recovery) within 6 months before screening 4. Occurrence of diabetic ketoacidosis, hyperosmolar coma, or lactic acidosis two or more times within 6 months prior to screening 5. Occurrence of any of the following events within 6 months prior to screening: acute myocardial infarction, unstable angina, coronary artery bypass grafting, percutaneous coronary intervention (excluding diagnostic angiography), transient ischemic attack, cerebrovascular accident, decompensated congestive heart failure, or Class III or IV heart failure (NYHA classification) 6. Significant weight change (weight gain or loss ≥5%) within 3 months prior to screening (as reported by the participant)
Study locations
China. Showing up to 24 locations stored in the fast local snapshot.
Tianjin Medical University General Hospital (Zhu Xianyi Memorial Hospital)
Tianjin, Tianjin Municipality, China
Publications
No PMID-linked publications were present in this registry snapshot.
Related trials
Ohio State University · Obesity & Overweight · Diabetes (DM)
Not applicable
Recruiting
300
2026-07
Eli Lilly · Type 2 Diabetes
Phase 3
Recruiting
55
2026-07
Eli Lilly · Diabetes Mellitus, Type 2
Phase 3
Not yet recruiting
170
2026-07
Brigham and Women's Hospital · Type 2 Diabetes
Not applicable
Completed
300,000
2026-07
Brigham and Women's Hospital · Type 2 Diabetes · Overweight
Not applicable
Completed
60,000
2026-07
Brigham and Women's Hospital · Type 2 Diabetes Mellitus · Obesity
Not applicable
Completed
120,000
2026-07
Eli Lilly · Type 2 Diabetes Mellitus
Phase 3
Completed
13,299
2026-07
ProGen. Co., Ltd. · Type 2 Diabetes
Phase 2
Not yet recruiting
60
2026-07
Related PeptideStat pages
Research pages describe evidence. Vendor pages, where available, describe independently tracked research-product listings and are not clinical recommendations.